Clinical differences between segmental nevus depigmentosus and segmental vitiligo

Roh, Dongyoung; Shin, Kihyuk; Kim, Woo-Il; Yang, Min‐Young; Lee, Won‐Ku; Kim, Gun‐Wook; Kim, Hoon‐Soo; Ko, Hyun‐Chang; Kim, Byung Soo; Kim, Moon-Bum

doi:10.1111/1346-8138.15015

Cited by 3 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 ND occurs sporadically with no known familial pattern of inheritance. 17 ND lesions can range in size from 1 cm to over 10 cm and rarely cross the midline. The larger lesions may mimic segmental vitiligo, as this form of vitiligo can be present at an early age.…”

Section: Nevus Depigmentosusmentioning

confidence: 99%

“…The larger lesions may mimic segmental vitiligo, as this form of vitiligo can be present at an early age. The term depigmentosus is Vitiligo differential diagnosis 1,13,15,[17][18][19]21 a misnomer, as individual lesions only appear depigmented in contrast to the complete depigmentation of vitiligo. As such, the lesions of ND show an off-white appearance but do not fluoresce under a Wood's lamp.…”

Section: Nevus Depigmentosusmentioning

confidence: 99%

“…As such, the lesions of ND show an off-white appearance but do not fluoresce under a Wood's lamp. 17 ND does not need to be treated unless the appearance affects the quality of life of the individual. Depending on the size of the lesion, one option for removal includes excision.…”

Section: Nevus Depigmentosusmentioning

confidence: 99%

“…Piebaldism is rarely associated with extracutaneous manifestations, unlike vitiligo, which is often associated with thyroid and metabolic disease. 17 Lastly, piebaldism tends to remain stable whereas vitiligo tends to progress.…”

Section: Piebaldismmentioning

confidence: 99%

“…Multiple small discrete "confetti" macules are also considered to be pathognomonic for TSC. 17 It is helpful to use a Wood's lamp to identify these characteristic hypomelanotic lesions. In addition to hypomelanotic lesions, 70% of cases will have angiofi bromas developing by age 1 to 4 years.…”

Section: Piebaldismmentioning

confidence: 99%

See 4 more Smart Citations

A practical guide to vitiligo differential diagnoses in primary care

Delgado

Crumpton

2021

The Nurse Practitioner

View full text Add to dashboard Cite

rimary care providers are often the fi rst to see and diagnose pigmentary disorders. A misdiagnosis of vitiligo can be made by even the most seasoned primary care provider and lead to delays in care and morbidity to the patient. It is imperative that the provider be familiar with various pigmentary disorders to provide safe and effective care as well as know when to expedite a referral to dermatology or other appropriate specialties. A signifi cant portion of these disorders includes hypopigmentation disorders such as vitiligo, pityriasis alba, nevus depigmentosus, nevus anemicus, idiopathic gutatte hypomelanosis, and piebaldism, in addition to certain signifi cant diagnoses such as tuberous sclerosis complex and localized scleroderma. This guide discusses common assessment characteristics that can help the primary care clinician build their clinical acumen so as to differentiate between the most common conditions of hypopigmentation and depigmentation without missing signifi cant diagnoses.

show abstract

Section: Nevus Depigmentosusmentioning

confidence: 99%

Section: Nevus Depigmentosusmentioning

confidence: 99%

Section: Nevus Depigmentosusmentioning

confidence: 99%

Section: Piebaldismmentioning

confidence: 99%

Section: Piebaldismmentioning

confidence: 99%

See 3 more Smart Citations

A practical guide to vitiligo differential diagnoses in primary care

Delgado

Crumpton

2021

The Nurse Practitioner

View full text Add to dashboard Cite

show abstract

Vitiligo: An Updated Narrative Review

Leung

Lam

Leung

et al. 2021

CPR

View full text Add to dashboard Cite

Background: Vitiligo is a relatively common acquired pigmentation disorder that can cause significant psychological stress and stigmatism. Objective: This article aims to familiarize physicians with the clinical manifestations, evaluation, diagnosis, and management of vitiligo. Methods: A Pubmed search was conducted in Clinical Queries using the key term "vitiligo". The search included metaanalyses, randomized controlled trials, clinical trials, observational studies, and reviews. The search was restricted to the English literature. The information retrieved from the above search was used in the compilation of the present article. The information retrieved from the above search was used in the compilation of the present article. Results: Approximately one quarter of patients with vitiligo have the onset before 10 years of age. Genetic, immunological, neurogenic and environmental factors may have a role to play in the pathogenesis. Vitiligo typically presents as acquired depigmented, well-demarcated macules/patches that appear milk- or chalk-white in color. Lesions tend to increase in number and enlarge centrifugally in size with time. Sites of predilection include the face, followed by the neck, lower limbs, trunk, and upper limbs. The clinical course is generally unpredictable. In children with fair skin, no active treatment is usually necessary other than the use of sunscreens and camouflage cosmetics. If treatment is preferred for cosmesis, topical corticosteroids, topical calcineurin inhibitors, and narrowband ultraviolet B phototherapy are the mainstays of treatment. Conclusion: The therapeutic effect of all the treatment modalities varies considerably from individual to individual. As such, treatment must be individualized. In general, the best treatment response is seen in younger patients, recent disease onset, darker skin types, and head and neck lesions. Topical corticosteroids and calcineurin inhibitors are the treatment of choice for those with localized disease. Topical calcineurin inhibitors are generally preferred for lesions on genitalia, intertriginous areas, face, and neck. Narrowband ultraviolet B phototherapy should be considered in patients who have widespread vitiligo or those with localized vitiligo associated with a significant impact on the quality of life who do not respond to treatment with topical corticosteroids and calcineurin inhibitors.

show abstract